Table 1 Targeting peptides that studied in the treatment of cancers

M-CTX-Fc

Glioblastoma

CD44

Increased bioavailability of DOX in U251MG-P1 glioblastoma cells. It was carried by liposomes

[30]

TAT

Nasopharyngeal carcinoma

CPP

Reduce the drug resistance and side effects of cisplatin

[34]

BR2

Cervical cancer, melanoma and colon cancer

CPP

Antiproliferative effects on HeLa, HCT116 and B16-F10 cells

[35]

cRGD

TNBC

αvβ3 integrin

Suppressed tumor growth with no noticeable side effects

[46]

cRGD

Lung

αvβ3 integrin

Increased bioavailability and anticancer effects of Dox

[47]

CTL-1

Glioma

Fibronectins

Increased inhibitive effects of PTX

[49]

MRP

Liver cancer

MMP-2

Increased antifibrotic effects of Pirfenidone

[50]

MTP-NRP1

Glioblastoma

NRP-1

Decreased cancer tissue angiogenesis due to this intervention

[51, 52]

SP2043

Breast cancer

IGF1R

Biomimetic peptide inhibits growth and metastasis of breast cancer by inhibiting the lymphangiogenesis and angiogenesis

[53]

TAT-ELP1-L12

Pancreatic adenocarcinoma

CPP

Enhance the antitumor effects of L12 peptide through dual targeting

[62]

GLVATVKEAGRSIHEIPREEL

Lymphoma

BCL6

Maintain the corepressor activity of BCL6 and prevent the unbridled increase of B cells

[72]

TAT-ETD

Hepatocarcinoma

CPP

HIF-1 activity and expression level reduction under hypoxia and finally reduced tumor growth by inhibiting angiogenesis

[73]